'PARAMEDIC-2:Big study, small result' by ter Avest, E. & Lameijer, H.
  
 University of Groningen
'PARAMEDIC-2





IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2019
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
ter Avest, E., & Lameijer, H. (2019). 'PARAMEDIC-2: Big study, small result'. Netherlands Heart Hournal,
27(7-8), 341-342. https://doi.org/10.1007/s12471-019-1302-x
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 13-11-2019
Point of View
Neth Heart J (2019) 27:341–342
https://doi.org/10.1007/s12471-019-1302-x
‘PARAMEDIC-2: Big study, small result’
E. ter Avest · H. Lameijer
Published online: 5 July 2019
© The Author(s) 2019
Abstract The PARAMEDIC-2 trial demonstrated that
the use of adrenaline compared with placebo in out-
of-hospital cardiac arrest (OHCA) resulted in a small
increase in 30-day survival, but was associated with
a higher number of survivors with severe neurological
impairment. These findings received a lot of atten-
tion, and generated a widespread discussion about
the role of adrenaline in cardiac arrest. In this point
of view, we aim to place the PARAMEDIC-2 results in
the right perspective by comparing the relative effect
of adrenaline to other determinants of cerebral blood
flow.
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Point of view
Last year, the authors of the PARAMEDIC2 trial
demonstrated that the use of adrenaline compared
with placebo in out-of-hospital cardiac arrest (OHCA)
resulted in a small increase in 30-day survival. In
addition, they showed that no significant between-
group difference in the rate of a favourable neuro-
logic outcome was observed, as more survivors had
severe neurologic impairment in the adrenaline group
[1]. These findings generated a widespread discus-
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sion around the use of adrenaline during cardiac
arrest, and resulted in the publication of multiple
commentaries focusing on the potential beneficial-
or detrimental effects of adrenalin in OHCA [2–4].
In our opinion, the focus of attention has been
too much on the potential detrimental effects of
adrenaline on neurological outcome in the aftermath
of the trial. Neurological outcome after OHCA is de-
pendent on oxygen delivery to the brain neurons. The
cumulative oxygen debit of the brain during the pe-
riod of arrest is related to the total amount of ‘missed
microcirculatory cerebral blood flow’ (CBF) during
the arrest, which is the product of the difference in
microcirculatory CBF before and during the arrest
and the total duration of the arrest (Fig. 1). Although
adrenaline has been shown to improve overall CBF, it
has a negative effect on cerebral microcirculation [2,
5].
Although this provides a pathophysiological mech-
anisms for the reported association between adren-
aline and a bad neurological outcome in the
PARAMEDIC-2 trial, other determinants of micro-
circulatory CBF likely had a far greater impact on
neurological outcome: 37% of the arrests in the
PARAMEDIC-2 trial were unwitnessed, and patients
received on average 21 minutes of CPR before a first
bolus of adrenaline was administered. These pro-
longed no-flow and resuscitation times likely had
a far greater impact on neurological outcome than
the (average dose of 4.9mg) adrenaline administered
(Fig. 1). This is supported by the (albeit not reported)
high number needed to harm for adrenaline in the
PARAMEDIC-2 trial: 39/4015 patients survived with
modified Rankin score of 4 or 5 in the adrenaline
group compared with 16/3999 in the placebo group,
resulting in a number needed to harm of 175.
In our opinion, attention should therefore be fo-
cused on the improvement of bystander CPR and early
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Fig. 1 Cerebral blood flow during cardiopulmonary resusci-
tation. Neurologic outcome of out-of-hospital cardiac arrest
(OHCA) is dependent on oxygen delivery to the brain, and
thereby on cerebral blood flow (CBF). CBF drops sharply to
0ml/min during cardiac arrest (a). Chest compressions reiniti-
ate CBF, but CBFwill not reach pre-arrest levels (b). Adrenaline
administration during cardiopulmonary resuscitation (c) may
result in a reduction of the (already compromised) CBF for
the duration of the half-life time of the adrenalin. When re-
turn of spontaneous circulation (ROSC) is reached, cerebral
blood flow is (gradually) restored to normal levels (d). The oxy-
gen debit of the brain during the period of arrest is correlated
to the total amount of ‘missed blood flow’ during the arrest,
which is the product of the difference in cerebral blood flow
before- and during the arrest and the total duration of the ar-
rest (shaded area). The relative contribution of adrenaline to
this area (crossed area) is only small
defibrillation rather than focusing on marginal gains
(or pains) of adrenaline administration during OHCA.
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